Insmed Incorporated (Nasdaq: INSM) announced the commercial launch of Brinsupri Tablets 25 mg (brensocatib hydrate) in Japan for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adults and pediatric patients 12 years and older.

Japan's Ministry of Health, Labour and Welfare approved Brinsupri in August 2026, based on results from the Phase 3 ASPEN study. The drug is an oral, once-daily, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), designed to inhibit neutrophil serine proteases that drive chronic airway inflammation in NCFB.

According to the company, Brinsupri is the first and only approved and commercially available treatment for NCFB in Japan. The drug is also approved in the United States in 10 mg and 25 mg formulations, and in the European Union and United Kingdom as a 25 mg tablet for patients with two or more exacerbations in the prior 12 months.

Bronchiectasis is a chronic lung condition characterized by permanently dilated bronchi resulting from cycles of infection, inflammation, and tissue damage. Symptoms include chronic cough, excessive sputum production, shortness of breath, and repeated respiratory infections.

In the ASPEN trial, the most common adverse reactions occurring in at least 2% of patients included upper respiratory tract infection, headache, rash, dry skin, hyperkeratosis, and hypertension. The drug carries warnings related to dermatologic and gingival reactions, and the use of live attenuated vaccines should be avoided during treatment.

Insmed is headquartered in Bridgewater, New Jersey, and has offices in the United States, Europe, and Japan.